z-logo
open-access-imgOpen Access
A New Phase II Agent Holds Promise for First FDA Approved Therapy for Treatment of Acute Vaso-Occlusive Pain Events in SCD
Author(s) -
Michael R. DeBaun
Publication year - 2017
Publication title -
the hematologist
Language(s) - English
Resource type - Journals
ISSN - 1551-8779
DOI - 10.1182/hem.v14.2.7115
Subject(s) - medicine , acute pain , intensive care medicine , pharmacology , anesthesia

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom